Ming Ye

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4.1K citations

Medicine, Oncology, Pharmacology +10

Cancer-associated Fibroblasts Promote Irradiated Cancer Cell Recovery Through Autophagy

Yongbin Wang, Guifang Gan, Bocheng Wang et al. · EBioMedicine · 2017 · 157 citations · Full text

Medicine, Cancer Biology, Oncology +17

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).

Caicun Zhou, Yi‐Long Wu, Xiaoqing Liu et al. · Journal of Clinical Oncology · 2012 · 79 citations

Medicine, Pharmacology, Cancer Pharmacology +7

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

Xiaoqing Yan, Ming Ye, Qing Zou et al. · Annals of Oncology · 2023 · 75 citations · Full text

Medicine, Oncology, Pharmacology +13

Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China

Bin Wu, Huafeng Chen, Ming Ye · Clinical Therapeutics · 2011 · 61 citations

Medicine, Oncology, Pharmacoeconomics +9